Physician profile
Patrick J Glencer
NPI 1417421611
$1,129.72
in general payments reported to CMS, 2019-2025
14 companies · $52.40 in 2025
The $52.40 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $143 · 2021: $141 · 2022: $266 · 2023: $179 · 2024: $247 · 2025: $52.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $214.90 | 2022-2025 | Envista Mx60 Iol, Vyzulta, Infuse |
| Aerie Pharmaceuticals, INC. | $213.98 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $153.05 | 2019-2022 | |
| Amgen INC. | $131.31 | 2024 | Tepezza |
| Abbvie INC. | $84.56 | 2022-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $80.26 | 2021-2023 | Tecnis Iol |
| Johnson & Johnson Vision Care, INC. | $73.38 | 2022-2024 | Acuvue |
| Alcon Vision LLC | $62.28 | 2022-2025 | Precision7 |
| Thea Pharma INC. | $24.30 | 2024 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.09 | 2021 | |
| Rxsight INC | $19.96 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Allergan, INC. | $18.74 | 2021 | |
| Biotissue Holdings INC. | $14.95 | 2022 | |
| Coopervision INC. | $13.96 | 2025 | Clariti Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Glencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.